Ramipril drug data and news

---

In normotensive hemodialysis patients, ramipril did not reverse ...  May 11, 2006
A 12-month treatment with ramipril did not cause significant regression of left ventricular hypertrophy in normotensive hemodialysis patients. ... - Therapeutics Daily (subscription) (press release),

Ramipril Improves Walking Ability in Patients with Peripheral ...  May 2, 2006
The summary below is from the full report titled "Brief Communication: Ramipril Markedly Improves Walking Ability in Patients with Peripheral Arterial Disease. ... - Annals of Internal Medicine

Brief Communication: Ramipril Markedly Improves Walking Ability in ...  May 2, 2006
...hypertension. Intervention: 10 mg of ramipril (n = 20) or placebo (n = 20) once daily for 24 weeks. All patients completed the trial. ... - Annals of Internal Medicine

Ramipril Lowers Diabetes Risk Among African Americans With ...  Apr 19, 2006
NEW YORK (Reuters Health) Apr 18 - Compared with metoprolol and amlodipine, ramipril treatment is associated with a lower risk of developing type 2 diabetes in ... - Medscape (subscription)

Heart drug eases clots in legs, study finds  May 2, 2006
..."We set about a six-month randomised clinical trial treating patients with a standard dose of Ramipril, with really amazing results - far beyond expectation ... - Australian,

Diabetes And Kidney  May 9, 2006
These special drugs are angiotensin converting enzyme inhibitors (ACE inhibitors such as enalapril, ramipril, lisinopril, etc.) or angiotensin receptor ... - Newindpress (subscription),

Speedel Announces Financial Results for First Quarter 2006  May 9, 2006
...on SPP100 (Rasilez) in hypertension as long-term monotherapy and in co-administration with amlodipine (calcium channel blocker) and ramipril (ACE inhibitor). ... - Yahoo! News (press release)

King Pharmaceuticals Reports First-Quarter 2006 Financial Results  May 9, 2006
...the utilization of business development to enhance our cardiovascular franchise with the in-licensing of novel formulations of Altace(R) (ramipril), and the ... - PR Newswire (press release),

Whites Only Medicine?  Apr 21, 2006
For example, this month researchers at the University of Alabama at Birmingham are reporting a study of the effects of ramipril—an angiotensin converting ... - Reason Online

Ace Inhibitors May Help Against Diabetes  Apr 17, 2006
...beneficial to blacks, but our analysis of the large, ongoing African-American Study of Kidney Disease and Hypertension showed the ace inhibitor ramipril to be ... - International News Service,

AACE: Aldactone Added to ACE or ARB Reduces Albuminuria in Type 2 ...  Apr 28, 2006
Standard medications included lisinopril, ramipril, quinapril, benazepril, and monopril as well as calcium channel blockers, beta-blockers, and diuretics. ... - MedPage Today,

With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.

With Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. If this is not possible, the starting dose should be reduced.

With Potassium Supplements and Potassium-sparing Diuretics: Ramipril can attenuate potassium loss caused by thiazide diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patient's serum potassium should be monitored frequently.

With Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.

Other: Neither ramipril nor its metabolites have been found to interact with food, digoxin, antacid, furosemide, cimetidine, indomethacin, and simvastatin. The combination of ramipril and propranolol showed no adverse effects on dynamic parameters (blood pressure and heart rate). The co-administration of ramipril and warfarin did not adversely affect the anticoagulant effects of the latter drug. Additionally, co-administration of ramipril with phenprocoumon did not affect minimum phenprocoumon levels or interfere with the subjects' state of anti-coagulation.